Abstract:The anthrapyrazole derivative biantrazole (7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2- hydroxyethyl)amino]ethyl]amino]-anthra[1,9-cd]pyrazol-6(2H)-one dihydrochloride, CI-941) is currently under clinical investigation for the treatment of breast cancer. Up to now, pharmacokinetic data of the drug were acquired using an HPLC assay lacking the capability to detect and separate metabolites of CI-941. Therefore an HPLC separation procedure was developed that is compatible with the ionization methods used most frequently for coupling to mass spectrometry. Application of the HPLC analysis to the urine of a patient treated with biantrazole clearly demonstrated the presence of two more polar metabolites. The molecular masses of the metabolites were determined during an HPLC-MS coupling with ionspray ionization after injection of an extract of only 15 ml of patient urine. Both metabolites have the same UV-VIS spectra as biantrazole and exhibit collision-induced mass spectra typical for aminoalkylamino-substituted anthrapyrazoles. The daughter ion mass spectra acquired during the HPLC separation allowed the identification of the chemical structures of both metabolites. Metabolite 1 was identified as the oxidation product of CI-941 with both side chains oxidized at the hydroxymethylene groups to the corresponding dicarboxylic acid derivative, whereas metabolite 2 was shown to be the analogous monooxidation product. However, the unsymmetrical molecular structure of CI-941 did not allow us to distinguish between two possible isomers of metabolite 2. Quantitation of the drug and its metabolites in patient urine collected during a time period of 100 hr showed that 0.55% of the dose were excreted as metabolite 1, 0.34% of the dose as metabolite 2, and 7.8% of the dose as unchanged drug.

Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS.

Determination of 5- N -Butyl-4-{4-[2-( 1H -Tetrazole-5-yl)- 1H -Pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)- 3H -1,2,4-triazol-3-one, a New Angiotensin Type 1 Receptor Antagonist in Rat Plasma by LC-ESI-MS: Application to Pharmacokinetic Studies

Characterization of the global metabolic profile of liquiritin in rat plasma, urine, bile and feces based on UHPLC-FT-ICR MS

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Bearing 5-Substituted Biphenyl-2-sulfonamide Derivatives As Potential Antihypertensive Candidates

Characterization of the metabolites of H3B-6545 in vitro and in vivo by using ultra-high performance liquid chromatography combined with electrospray ionization linear ion trap-orbitrap tandem mass spectrometry

Characterization of Angiotensin II Antagonism Displayed by Ib, a Novel Nonpeptide Angiotensin AT1 Receptor Antagonist

Identification Of The Metabolite Of 7-(4-Chlorbenzyl)-7,8,13,13a-Tetrahydroberberine Chloride In Rat Bile By Lc/Ms And Lc/Nmr

Study of the in Vitro Metabolism of Tj0711 Using Ultra High Performance Liquid Chromatography with Quadrupole Time-Of-Flight and Ultra Fast Liquid Chromatography with Quadrupole Linear Ion Trap Mass Spectrometry

Pharmacokinetics and Metabolite Identification of a Novel VEGFR-2 and Src Dual Inhibitor 6-Chloro-2-methoxy-n-(2-methoxybenzyl) Acridin-9-amine in Rats by Liquid Chromatography Tandem Mass Spectrometry

Investigation of the Metabolism of 7-(4-chlorbenzyl)7,8,13,13a-tetrahydroberberine Chloride in the Rat

Detection and identification of human urinary metabolites of biantrazole (CI-941)

[Stereoselectivity in Biliary Excretion of Trans Tramadol and Trans O-demethyltramadol in Rats].

Liquid chromatography-tandem mass spectrometry analysis of protocatechuic aldehyde and its phase I and II metabolites in rat.

Metabolism of 20(S)-Ginsenoside Rg2 by Rat Liver Microsomes: Bioactivation to SIRT1-Activating Metabolites

Identification of Ginkgolic Acid (15:1) Metabolites in Rats Following Oral Administration by High-Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry

Metabolite identification of tanshinol borneol ester in rats by high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight mass spectrometry

Pharmacokinetics, Tissue Distribution and Excretion of ACT001 in Sprague-Dawley Rats and Metabolism of ACT001.

Study on the Stereoselective Excretion of Tetrahydropalmatine Enantiomers in Rats and Identification of in Vivo Metabolites by Liquid Chromatography-Tandem Mass Spectrometry.